Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study
- PMID: 31015203
- PMCID: PMC6606380
- DOI: 10.1158/1055-9965.EPI-18-1235
Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study
Abstract
Background: Pancreatic cancer is the fourth-leading cause of cancer death in both men and women in the United States. The currently identified common susceptibility loci account for a small fraction of estimated heritability. We sought to estimate overall heritability of pancreatic cancer and partition the heritability by variant frequencies and functional annotations.
Methods: Analysis using the genome-based restricted maximum likelihood method (GREML) was conducted on Pancreatic Cancer Case-Control Consortium (PanC4) genome-wide association study (GWAS) data from 3,568 pancreatic cancer cases and 3,363 controls of European Ancestry.
Results: Applying linkage disequilibrium- and minor allele frequency-stratified GREML (GREML-LDMS) method to imputed GWAS data, we estimated the overall heritability of pancreatic cancer to be 21.2% (SE = 4.8%). Across the functional groups (intronic, intergenic, coding, and regulatory variants), intronic variants account for most of the estimated heritability (12.4%). Previously identified GWAS loci explained 4.1% of the total phenotypic variation of pancreatic cancer. Mutations in hereditary pancreatic cancer susceptibility genes are present in 4% to 10% of patients with pancreatic cancer, yet our GREML-LDMS results suggested these regions explain only 0.4% of total phenotypic variance for pancreatic cancer.
Conclusions: Although higher than previous studies, our estimated 21.2% overall heritability may still be downwardly biased due to the inherent limitation that the contribution of rare variants in genes with a substantive overall impact on disease are not captured when applying these commonly used methods to imputed GWAS data.
Impact: Our work demonstrated the importance of rare and common variants in pancreatic cancer risk.
©2019 American Association for Cancer Research.
Conflict of interest statement
Conflicts of Interest: The authors declare no potential conflicts of interest.
Figures



References
-
- Cancer Facts & Figures 2018. [Internet]. [cited 2018 April 25]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-...
-
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014. June 1;74(11):2913–21. - PubMed
Publication types
MeSH terms
Grants and funding
- HHSN261201000140C/CA/NCI NIH HHS/United States
- U24 CA074783/CA/NCI NIH HHS/United States
- HHSN268201100011I/HL/NHLBI NIH HHS/United States
- HHSN268201100011C/HL/NHLBI NIH HHS/United States
- P50 CA102701/CA/NCI NIH HHS/United States
- R01 CA109767/CA/NCI NIH HHS/United States
- R01 CA154823/CA/NCI NIH HHS/United States
- U01 CA074783/CA/NCI NIH HHS/United States
- R01 CA097075/CA/NCI NIH HHS/United States
- 001/WHO_/World Health Organization/International
- R03 CA123546/CA/NCI NIH HHS/United States
- P50 CA062924/CA/NCI NIH HHS/United States
- P30 CA006973/CA/NCI NIH HHS/United States
- R01 CA098870/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- U01 CA167551/CA/NCI NIH HHS/United States
- U58 DP003862/DP/NCCDPHP CDC HHS/United States
- WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Medical